Erez Vigodman, 54, a board member at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), will probably appoint the new CEO of the world’s largest generic drug maker company. Other finalists for the job are Eyal Desheh, Teva’s acting chief executive and longtime chief financial officer, and Austrian Ratiopharm GmbH and Actavis Inc leader, Claudio Albrecht.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Mr. Vigodman has been a Teva board member since 2009 and served as the CEO of Agrochemicals maker Makhteshim Agan Industries Ltd. Before that, he was the CEO of food company Strauss Group Ltd. (TASE:STRS). Mr. Vigodman will appoint to the job that has been open since Jeremy Levin abruptly left Teva in October 2013, as a result of “light” disagreements with the board.
Among the tasks ahead Mr. Vigodman needs to lead Teva’s ship through hard times, as the company expected competition for its flagship product, the Copaxone for multiple-sclerosis therapy. Copaxone’s US patents expires in May 2014, and it contributes an estimated 50-70% of Teva’s profits. It accounted for $4 billion of Teva’s $20 billion in 2012 sales but soon it will face competition mainly from low-cost generic drug makers from India. Teva’s net incomealready fell from $3.3 billion in 2010 to $1.9 billion in 2012.
Teva hired global headhunting firm Egon Zehnder for the search, and it has reviewed a large number of candidates for the job in the past few weeks.